Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection

ABSTRACT Most human immunodeficiency virus type 1 (HIV-1)-infected individuals develop an HIV-specific neutralizing antibody (NAb) response that selects for escape variants of the virus. Here, we studied autologous NAb responses in five typical CCR5-using progressors in relation to viral NAb escape and molecular changes in the viral envelope (Env) in the period from seroconversion until after AIDS diagnosis. In sera from three patients, high-titer neutralizing activity was observed against the earliest autologous virus variants, followed by declining humoral immune responses against subsequent viral escape variants. Autologous neutralizing activity was undetectable in sera from two patients. Patients with high-titer neutralizing activity in serum showed the strongest positive selection pressure on Env early in infection. In the initial phase of infection, gp160 length and the number of potential N-linked glycosylation sites (PNGS) increased in viruses from all patients. Over the course of infection, positive selection pressure declined as the NAb response subsided, coinciding with reversions of changes in gp160 length and the number of PNGS. A number of identical amino acid changes were observed over the course of infection in the viral quasispecies of different patients. Our results indicate that although neutralizing autologous humoral immunity may have a limited effect on the disease course, it is an important selection pressure in virus evolution early in infection, while declining HIV-specific humoral immunity in later stages may coincide with reversion of NAb-driven changes in Env.

[1]  Yang Liu,et al.  Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  W. Blattner,et al.  Reversal of Human Immunodeficiency Virus Type 1 IIIB to a Neutralization-Resistant Phenotype in an Accidentally Infected Laboratory Worker with a Progressive Clinical Course , 2001, Journal of Virology.

[3]  G. Groen,et al.  Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV p24gag. , 1989, Virology.

[4]  J. Overbaugh,et al.  Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies , 1997, Journal of virology.

[5]  E. Fenyö,et al.  Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. , 1997, The Journal of infectious diseases.

[6]  J. Sodroski,et al.  Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein , 1997, Journal of virology.

[7]  T. A. Hall,et al.  BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT , 1999 .

[8]  J. Mascola,et al.  The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope , 2004, Journal of Virology.

[9]  L. Stamatatos,et al.  An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades , 1998, Journal of Virology.

[10]  J. Margolick,et al.  HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. , 1996, Journal of immunology.

[11]  A Muñoz,et al.  A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. , 1999, The Journal of infectious diseases.

[12]  Jun Li,et al.  Antiviral Antibodies Are Necessary for Control of Simian Immunodeficiency Virus Replication , 2007, Journal of Virology.

[13]  D. Montefiori,et al.  Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. , 1997, The Journal of infectious diseases.

[14]  J. Albert,et al.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.

[15]  J. M. González,et al.  A fluorimetric method for the estimation of G+C mol% content in microorganisms by thermal denaturation temperature. , 2002, Environmental microbiology.

[16]  D. Nickle,et al.  Human Immunodeficiency Virus Type 1 env Evolves toward Ancestral States upon Transmission to a New Host , 2006, Journal of Virology.

[17]  Sergei L. Kosakovsky Pond,et al.  Synonymous Substitution Rates Predict HIV Disease Progression as a Result of Underlying Replication Dynamics , 2007, PLoS Comput. Biol..

[18]  J. Overbaugh,et al.  Human Immunodeficiency Virus Type 1 V1-V2 Envelope Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection, and These Modifications Affect Antibody Neutralization Sensitivity , 2006, Journal of Virology.

[19]  H. Schuitemaker,et al.  Molecular Evolution of Human Immunodeficiency Virus Type 1 upon Transmission between Human Leukocyte Antigen Disparate Donor-Recipient Pairs , 2008, PloS one.

[20]  Don C. Wiley,et al.  Structure of an unliganded simian immunodeficiency virus gp120 core , 2005, Nature.

[21]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[22]  D. Ho,et al.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.

[23]  Amanda M. Brown,et al.  Selection for Neutralization Resistance of the Simian/Human Immunodeficiency Virus SHIVSF33A Variant In Vivo by Virtue of Sequence Changes in the Extracellular Envelope Glycoprotein That Modify N-Linked Glycosylation , 1999, Journal of Virology.

[24]  L. Stamatatos,et al.  The V1, V2, and V3 Regions of the Human Immunodeficiency Virus Type 1 Envelope Differentially Affect the Viral Phenotype in an Isolate-Dependent Manner , 2005, Journal of Virology.

[25]  H. Katinger,et al.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. , 1999, Immunity.

[26]  Christos J. Petropoulos,et al.  Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses , 2006, Journal of Virology.

[27]  B. Korber,et al.  The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. , 2004, Virology.

[28]  Hui Li,et al.  Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.

[29]  Robert F. Siliciano,et al.  Maintenance of viral suppression in HIV-1–infected HLA-B*57+ elite suppressors despite CTL escape mutations , 2006, The Journal of experimental medicine.

[30]  F. Bibollet-Ruche,et al.  Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection , 2007, Journal of Virology.

[31]  Christos J. Petropoulos,et al.  Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus , 2006, The Journal of experimental medicine.

[32]  H. Schuitemaker,et al.  Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies , 2007, Journal of Virology.

[33]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Bustamante,et al.  A statistical characterization of consistent patterns of human immunodeficiency virus evolution within infected patients. , 2005, Molecular biology and evolution.

[35]  B. Walker,et al.  Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. , 1996, AIDS research and human retroviruses.

[36]  H. Schuitemaker,et al.  Increased Sensitivity to CD4 Binding Site-Directed Neutralization following In Vitro Propagation on Primary Lymphocytes of a Neutralization-Resistant Human Immunodeficiency Virus IIIB Strain Isolated from an Accidentally Infected Laboratory Worker , 2004, Journal of Virology.

[37]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[38]  Peter D. Kwong,et al.  Antigenic conservation and immunogenicity of the HIV coreceptor binding site , 2005, The Journal of experimental medicine.

[39]  Bette Korber,et al.  Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. , 2004, Glycobiology.

[40]  H. Schuitemaker,et al.  Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. , 2003, The Journal of infectious diseases.

[41]  D. Burton,et al.  Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.

[42]  H. Fleury,et al.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals , 1997, Journal of virology.

[43]  R. Doms,et al.  Relationships between CD4 Independence, Neutralization Sensitivity, and Exposure of a CD4-Induced Epitope in a Human Immunodeficiency Virus Type 1 Envelope Protein , 2001, Journal of Virology.

[44]  S. Zolla-Pazner Improving on nature: focusing the immune response on the V3 loop. , 2006, Human antibodies.

[45]  H. Schuitemaker,et al.  In Vivo Evolution of X4 Human Immunodeficiency Virus Type 1 Variants in the Natural Course of Infection Coincides with Decreasing Sensitivity to CXCR4 Antagonists , 2004, Journal of Virology.

[46]  S. Zolla-Pazner,et al.  The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection , 2004, Journal of Virology.

[47]  P. Jolly,et al.  Neutralization and enhancement of HIV-1 infection by sera from HIV-1 infected individuals who progress to disease at different rates. , 2000, Virology.

[48]  M. Salimans,et al.  Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.

[49]  B. Korber,et al.  Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques , 2006, Journal of Virology.

[50]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.